BIOMAT Database Logo BIOMAT Database Logo

Tumor-associated trypsin inhibitor (TATI) in pleural effusions. 1991

M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Department of Respiratory Physiology, Molinette Hospital, Torino, Italy.

The purpose of this study was to evaluate the usefulness of tumor-associated trypsin inhibitor (TATI) determination in serum and pleural fluid for differential diagnosis of relapsing pleural effusions. The concentrations of TATI were determined in samples of serum and pleural fluid from 51 patients with pleural effusions comprising 20 benign exudates, 5 transudates and 26 malignant effusions. TATI levels overlapped in benign and malignant fluids. This precludes the use of this marker for diagnosis of pleural effusions. For this purpose CEA seems to be the best tumor marker with a sensitivity frequently higher than that of cytology.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D010996 Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself. Effusion, Pleural,Effusions, Pleural,Pleural Effusions
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014359 Trypsin Inhibitor, Kazal Pancreatic A secreted KAZAL MOTIF-containing serine peptidase inhibitor that inhibits TRYPSIN. It is a protein composed of 56 amino acid residues and is different in amino acid composition and physiological activity from the Kunitz bovine pancreatic trypsin inhibitor (APROTININ). It protects against the trypsin-mediated premature activation of ENZYME PRECURSORS in the PANCREAS. Mutations in the SPINK1 gene are associated with CHRONIC PANCREATITIS. Acidic Pancreatic Trypsin Inhibitor,Kazal Pancreatic Trypsin Inhibitor,Pancreatic Secretory Trypsin Inhibitor, Kazal,Pancreatic Trypsin Secretory Inhibitor, Kazal,Trypsin Inhibitor, Pancreatic Secretory,Inhibitor, Tumor-Associated Trypsin,Pancreatic Secretory Trypsin Inhibitor,SPINK1,Serine Peptidase Inhibitor, Kazal-Type 1,Serine Protease Inhibitor Kazal-Type 1,Trypsin Inhibitor Kazal Pancreatic,Trypsin Inhibitor, Tumor-Associated,Tumor-Associated Trypsin Inhibitor,Serine Peptidase Inhibitor, Kazal Type 1,Serine Protease Inhibitor Kazal Type 1,Trypsin Inhibitor, Tumor Associated,Tumor Associated Trypsin Inhibitor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Concentration of tumor-associated trypsin inhibitor (TATI) in pleural effusions.
November 1990, Chest,
M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Tumor-associated trypsin inhibitor (TATI) and renal function.
December 1997, Kidney international. Supplement,
M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma.
January 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum,
M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Biology and function of tumor-associated trypsin inhibitor, TATI.
January 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum,
M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Validation and comparison of tumor-associated trypsin inhibitor (TATI) immunoassays.
August 2012, Clinica chimica acta; international journal of clinical chemistry,
M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
January 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum,
M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
June 2020, Acta oncologica (Stockholm, Sweden),
M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
March 1988, British journal of cancer,
M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
January 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum,
M Rapellino, and F Pecchio, and S Baldi, and M R Adamo, and M Macri, and G Ricardi
[Clinical evaluation of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological tumor].
March 1993, Nihon Sanka Fujinka Gakkai zasshi,
Copied contents to your clipboard!